Genmab A (GMAB) Operating Income (2024 - 2026)
Genmab A's (GMAB) quarterly Operating Income came in at $180.0 million in Q1 2026, down 4.26% YoY from $188.0 million in Q1 2025, and down 82.13% on a QoQ basis from $1.0 billion in Q3 2025.
Genmab A (GMAB) Operating Income (2024 - 2026) Analysis & Trends
Genmab A (GMAB) has 3 years of Operating Income data on file, last reported at $180.0 million in Q1 2026.
- Quarterly Operating Income fell 4.26% year-over-year to $180.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 45.9% YoY) and the FY2025 annual result came in at $1.1 billion, up 9.57% from the prior year.
- Operating Income slipped to $180.0 million in Q1 2026, from $1.0 billion in the prior quarter.
- In the past five years, Operating Income ranged from a high of $1.0 billion in Q3 2025 to a low of $116.0 million in Q1 2024.
- A 3-year average of $436.1 million and a median of $352.0 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2025 — Operating Income surged 62.07% — and 2026, when it dropped 4.26%.
- Tracing GMAB's Operating Income over 3 years: stood at $662.0 million in 2024, then surged by 52.11% to $1.0 billion in 2025, then sank by 82.13% to $180.0 million in 2026.
- The last three Operating Income figures came in at $180.0 million (Q1 2026), $1.0 billion (Q3 2025), and $548.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 375.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 375.00 Mn |
| Mar 31, 2026 | 180.00 Mn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | 548.00 Mn |
| Mar 31, 2025 | 188.00 Mn |
| Sep 30, 2024 | 662.00 Mn |
| Jun 30, 2024 | 352.00 Mn |
| Mar 31, 2024 | 116.00 Mn |